News Archives for August 2018

Recent News

ASGCT Supports NIH/RAC Recommendation

While the RAC serves a valuable role as an essential public forum for science, safety, and ethics, the current requirements for gene therapies have proven redundant.

FDA Approves Patisiran, First-Ever RNA Interference Therapeutic Approved for Clinical Use
August 16, 2018

Infusions of Onpattro (Alnylam Pharmaceuticals) is the first therapeutic to treat peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) approved by the U.S. Food and Drug Administration, in addition to the first targeted RNA-based gene therapy.

ASGCT Releases Anti-Harassment Policy
August 03, 2018

The fields of gene and cell therapy are strongest when all members are supported by positive, safe, and healthy work environments. To reinforce a healthy environment for all, the ASGCT Trainee and Executive committees established a new mandatory anti-harassment and non-discrimination policy for all ASGCT events.

22nd Annual Meeting
April 29 – May 2 | Washington D.C.